Recent Event Highlights: FDA Splits with Panel; Approves Tarceva in NSCLC Maintenance - BioWorld Online, RHHBY.PK - Looks like a very compelling buy after earnings and breast cancer ... - Motley Fool (blog), Roche, OSI win US approval for wider Tarceva use - Reuters, Avastin for lung and colon cancer, New Roche NimbleGen Service Now With 2 Micron Scanning on the MS 200 Scanner - MarketWatch (press release), Roche sales climb 6% on cancer-drug demand - MarketWatch, and 43 more...
Created by dipity on Mar 12, 2009
Last updated: 09/21/10 at 05:58 PM
Roche Genentech has no followers yet. Be the first one to follow.
FDA Splits with Panel; Approves Tarceva in NSCLC MaintenanceBioWorld OnlineIn NSCLC, the standard of care is first-line treatment with either chemotherapy or chemotherapy plus targeted drug Avastin (bevacizumab, Genentech/Roche). ...OSI/Genentech gain additional indication from US FDA for Tarceva as ...The Pharma LetterAdditional Indication for OSI Drug - Analyst BlogBenzingaall 38 news articles »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.bioworld.com%2Fservlet%2Fcom.accumedia.web.Dispatcher%3Fnext%3DbioWorldHeadlines_article%26forceid%3D54249&usg=AFQjCNHA5raNI57oILXC_wKlFeakNjubrg
Three Small-Cap Biotech Stocks with PotentialWealth DailyThey were bought by Roche in 2009. Early investors made a killing. The fact that Genentech is teaming up with a tiny company like CRIS is reassuring. ...
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.wealthdaily.com%2Farticles%2Fbiotech-stocks%2F2440&usg=AFQjCNGJDrMggJdm0MfoCEuWwzKAQkmTyg
RHHBY.PK - Looks like a very compelling buy after earnings and breast cancer ...Motley Fool (blog)... Roche disclosed that co representatives have had discussions with the FDA and that, based on these discussions, Genentech/Roche plans to submit a ...
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fcaps.fool.com%2FBlogs%2FViewPost.aspx%3Fbpid%3D378979%26t%3D01004525939372753684&usg=AFQjCNHTQpZ4FlBAiXdHYCI3JMIDT-EVvw
Roche, OSI win US approval for wider Tarceva useReuters... people fight the leading cause of cancer death in the United States," Hal Barron, chief medical officer at Roche's Genentech unit said in a statement. ...FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung ...dBusinessNews Sacramento (press release)all 19 news articles »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.reuters.com%2Farticle%2FidUSN1616855620100417%3Ftype%3DmarketsNews&usg=AFQjCNFbjHp9DoNuu5qq3X8sHyKJN9uyiA
New Roche NimbleGen Service Now With 2 Micron Scanning on the MS 200 ScannerMarketWatch (press release)Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. ...and more »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.marketwatch.com%2Fstory%2Fnew-roche-nimblegen-service-now-with-2-micron-scanning-on-the-ms-200-scanner-2010-04-15%3Freflink%3DMW_news_stmp&usg=AFQjCNEepyK18xO7ZRgIJhPYJnN8dXTdrA
TopNews United StatesRoche sales climb 6% on cancer-drug demandMarketWatchBy year's end, Roche also is targeting repayment of a quarter of the debt it incurred last year from buying the 44% of Genentech it didn't previously own ...Roche Boosted By Cancer Drugs, Emerging MarketsWall Street JournalRoche Sales Grow on Cancer Drug DemandDailyFinanceCancer drug highly profitable for RocheBrunei NewsThe Pharma Letter -Pharma Times -San Francisco Chronicleall 240 news articles »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.marketwatch.com%2Fstory%2Froche-sales-climb-6-on-cancer-drug-demand-2010-04-15%3Freflink%3DMW_news_stmp&usg=AFQjCNGQoShfsuBw5M4MTT1IZPAt4Zbmaw
ImmunoGen, Inc. Announces Favorable Update Provided by Roche Related to Its ...MarketWatch (press release)The most advanced compound, T-DM1, is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer ...ImmunoGen Inc reports on progress towards marketing application for T-DM1Trading Markets (press release)Roche Keeps Its PromisesWall Street Journal (blog)Roche Picks Up Pace on ImmunoGen Antibody Drug ConjugateSeeking Alpha (blog)all 43 news articles »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.marketwatch.com%2Fstory%2Fimmunogen-inc-announces-favorable-update-provided-by-roche-related-to-its-trastuzumab-dm1-regulatory-plans-2010-04-15%3Freflink%3DMW_news_stmp&usg=AFQjCNHj-4eEATbWShEVRLvbAYzEyyBgpA
Affymax Hires Genentech Exec Orwin As Operating ChiefWall Street JournalOrwin previously worked at Genentech Inc., a unit of Roche Holding AG (RHHBY, ROG.VX), where he was responsible for all marketing, sales, business unit ...and more »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fonline.wsj.com%2Farticle%2FBT-CO-20100412-711940.html%3Fmod%3DWSJ_latestheadlines&usg=AFQjCNEPl3IZpZ0XSrQT5YHTRYnbFCb2fw
Roche Shuns 'Not Invented Here Syndrome' to Boost Sales, ProfitBusinessWeekWeiss recommends buying Roche shares. Genentech developed the Swiss drugmaker's three top medicines. Avastin, the world's best-selling cancer medicine, ...Roche: Still looking for deals in 2010FierceBiotechRoche Has No Plans To Withdraw From UKWall Street JournalNovartis and Roche threaten to quit UKThe GuardianFiercePharma -Corante (blog) -Motley Foolall 16 news articles »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.businessweek.com%2Fnews%2F2010-04-12%2Froche-shuns-not-invented-here-syndrome-to-boost-sales-profit.html&usg=AFQjCNGJTFH-o4TlMllZcq9H4gqYCDiNFw
Dendreon Appoints VPNorthwest innovationNanda joins the firm from Roche/Genentech, where he was Senior Vice President and Global Head of Oncology. Nanda has also served at Avastin, Genentech, ...Dendreon hires Roche execTechFlash (blog)Dendreon Hires Roche Sales BossSeattle Post IntelligencerDendreon Appoints Varun Nanda Senior Vice President of Global Commercial ...CNNMoney.com (press release)all 17 news articles »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.nwinnovation.com%2Fstory%2F0027927.html&usg=AFQjCNE6gST3ikPeHV9hWU_eoGXhupbxsg
blogtv www.blogtv.com REVBEESUTUBE www.youtube.com REV B Space www.myspace.com twitter twitter.com facebook www.facebook.com zazzle www.zazzle.com Rev B Site www.reverendb.com dailybooth.com dailybooth.com
VOTE Today -11/30/09 To Help TYT Beat Limbaugh: www.theyoungturks.com Watch more at www.theyoungturks.com and follow us on Twitter at http
Back in 1993, I was blessed to be part of the Pulmozyme drug study by Genentech (Roche). I felt so much better after taking the inhaled drug Pulmozyme, I decided to create a VHS video for the scientist behind this drug, Dr.Shak.. I wrote the rap song and went to The Ft. Lauderdale's children theatre who helped me to bring the words to life. This project took us three months to complete. Enjoy! Please visit transplantbuddies.org to chat with me an other pre and post transplant buddies. Rise'
Art and Sue deliver a short but thoughtful speech during the "Hearts for Art" rally at Genentech on March 27, 2009
www.phcconsulting.com www.career-confidential.com Peggy McKee gives the top tips for getting into medical, healthcare, laboratory or pharmaceutical sales. She explains how to use your resume, keywords, job shadowing, your network and the internet to prepare yourself for success in a medical sales job. Check out her site at www.phcconsulting.com or send your resume to resumes@phcconsulting.com www.phcconsulting.com www.career-confidential.com
Swiss pharmaceutical giant Roche has agreed to pay $46.8 billion to buy the 44 percent of California-based biotech pioneer Genentech that it doesn't already own. The AP's Mark Hamrick reports. (March 12)
Roche took a lower price to shareholders, then genentech finally said yes to a somewhat higher $46.8billion deal. (Bloomberg News)
Self Bank es un banco on line . Te regalamos 1.000 euros en comisiones de bolsa si aún no eres cliente. Visítanos en www.selfbank.es. Los índices europeos abren con descensos, de alrededor de un 1%. El rebote de las dos últimas sesiones ha terminado esta madrugada en Japón, donde el Nikkei ha caído un -2,41% hasta los 7.198,25 puntos, a pesar de que Wall Street cerró en positivo. En el plano empresarial destacan los rumores de alianza estratégica entre Telefónica y Vodafone en Reino Unido para compartir infraestructuras. Carrefour ha publicado resultados por debajo de lo estimado. En el sector farmacéutico Roche acuerda pagar 95 dólares por cada acción de Genentech, es decir, 46.800 millones de dólares, oferta que por fin ha aceptado la americana. En España, Endesa presenta su Plan Estratégico 2009-2013 y anuncia inversiones por valor de 13.500 millones de euros
Excerpt
...operate as an independent center within Roche from its existing campus in South San Francisco, it said. The size of the Roche-Genentech deal eclipses the $39 billion takeover of U.S. eye care company Alcon announced last April by Roche's Swiss rival Novartis...
Source Info
PR-Inside.com
http://www.pr-inside.com/roche-to-take-over-genentech-for-r1109238.htm
Excerpt
...Let Genentech continue to be the innovative company it has been in the past and let it continue to help patients. Roche taking over Genentech will only take away from this. I don’t know of a single Genentech employee that wants this deal to happen. Roche should...
Source Info
The New York Times
http://feeds.nytimes.com/click.phdo?i=7147f6a7fd621cc6561a99bb5614a3c4
Excerpt
...it is offering to pay. David A. Ebersman, Genentech’s chief financial officer, drew applause when he showed how dependent Roche already was on Genentech. He put up a chart showing dozens of clinical trials that Roche is conducting. When he then stripped out...
Source Info
The New York Times
http://feeds.nytimes.com/click.phdo?i=c9355a72488d899ab46f2e773989c579
Excerpt
...top scientists. In addition to stressing that the biotech company would operate as an independent unit within Roche and retain the Genentech name, Roche has said it also would let Genentech stay where it is and beef up its South San Francisco site by moving...
Source Info
The San Jose Mercury News
http://www.mercurynews.com/business/ci_11741583?source=rss
Roche Begins Hostile Takeover Bid for Genentech at $86.50, Amex Biotech Index +10% YTD, Biotechs Rally; Profits Soaring; Report and analysis by Andrew Cinko of Bloomberg News (Starting Bell)
Excerpt
...continue the existing relationship where [Genentech] operates with substantial autonomy despite Roche's majority ownership." Genentech and Goldman Sachs finally proposed a valuation analysis to Roche in December with a range of $112 to $115 a share, but indicated...
Source Info
MarketWatch
http://feeds.marketwatch.com/~r/marketwatch/financial/~3/nvv_BpHobjo/story.aspx
Excerpt
...a 14.7 percent premium to Genentech's closing price on July 14, the last trading day a week before Roche's original $89 bid, Roche said. Genentech shares dropped 30 cents, or 0.36 percent, to close at $82.70 Monday, but gained 30 cents in after-hours trading. This...
Source Info
San Francisco Chronicle
http://feeds.sfgate.com/click.phdo?i=9055901915626977723c5109fd979d3f
Sean Butler gives his morning summary and outlook for the world markets February 4, 2008.
Thailand?s banks are seeking a $1 point 54 billion state aid package. Also, Roche lowers Genentech bid.
Roche Turns Hostile, Taking $44 Billion Offer for Genentech Straight to Shareholders; BNP Paribas Take on More Toxic Assets to Save Fortis Deal; Porsche's First Half Sales Down 27%, Revenue Down 14%; In Other News, Italian Mafia Had $167 Billion in Revenu
Los índices europeos cayeron ayer y vuelven a recortar hoy en la apertura. Vemos como los bancos siguen recogiendo beneficios después de la fiesta del pasado miércoles. Tranquiliza ver a Telefónica cayendo menos que el mercado, al menos de momento, después de varias jornadas con un comportamiento relativo claramente malo. Hay noticias importantes para BNP Paribas, que parece haber llegado a un acuerdo para comprar una participación pequeña del 10%- en el negocio asegurador de Fortis, al ...
A version of Misty adapated to the circumstances of Genentech
Yesterday adapted to current circumstances of Genentech
You are Watching: Genentech / Roche, Good Time for a Deal; Talent Unlikely to be Retained, says Katherine Kim [BoA] Genentech is at a turning point, and the time would be right for an acquisition by Roche (if there were any). Her price target is $110 per share. Katherine and Daniel review the value drivers in Genentech, and the willingness of both Roche and Genentech CEOs to make this deal happen. This interview was conducted at the NASDAQ Marketsite, on August 25th, 2008, in New York City ...
You are Watching: Roche and Genentech, Deal Review, with Mike King. Mike King and Daniel Teper discuss the Genentech / Roche deal. Genentechs Board of Directors say $89 per share is inadequate, Roches management feels it is more than generous. Genentech shareholders like this stock, and are reluctant to sell for less than $120-135. Why does Roche want the remaining 56% of Genentech? Will Roche be able to retain the innovation that made Genentech so successful? What are the odds of this deal ...
You are Watching: BMS and ImClone Deal Review, with Mike King. Why is BMS after ImClone, and what will happen next? Carl Icahns says the $60 bid is too low. Mike King believes Icahn is waiting for the Genentech Roche transaction to play out, in order to see the valuation metrics that will be used in that transaction. Mike and Daniel continue to discuss the integration of ImClone within BMS, the international rights to Erbitux, and the odds of this transaction closing. This interview was ...
You are Watching: Visionaries: Bill Kridel on the Role of M&A Today. Bill Kridel discusses the strategic and rescue role of M&A today. Many companies leverage M&A for geographic and portfolio reasons - looking at some of the latest deals (Roche and Genentech, Daiichi and Ranbaxy). With the current market conditions M&A propositions from larger companies are becoming increasingly attractive. This interview was conducted at the NASDAQ Marketsite, on July 23rd, 2008, in New York City. Featuring ...
Excerpt
...(NYSE: BMY) offer for ImClone Systems (Nasdaq: IMCL) this year -- have shown. Secondly, because of its relationship with Genentech, Roche gets automatic first dibs on marketing rights to any Genentech drug that gets approved for sale outside of the U.S. This...
Source Info
The Money Times
http://feeds.feedburner.com/~r/TheMoneyTimes/~3/365602215/genentech_asks_roche_to_pay_up-id-1032776.html
Excerpt
...retention program "to address any employee concerns created by the Roche proposal," Genentech's statement said. The company's board had previously given the committee power to create such a program. Roche likely won't waste time making a new bid to take complete...
Source Info
The San Jose Mercury News
http://www.mercurynews.com/business/ci_10192982?source=rss
Excerpt
...offer, which represented a 30% premium above the price of ImClone shares before the offer was made, was too low. Roche's offer to Genentech offered an 8.8% premium. Roche spokesman Al Wasilewski says Roche still believes its offer is "fair and generous." Genentech...
Source Info
USA Today
http://www.usatoday.com/money/industries/health/drugs/2008-08-13-genentech-rejects-roche_N.htm?csp=34
Excerpt
...Genentech shares. In part of the legal complaint called a derivative claim, the attorneys are asking a judge to declare the Genentech-Roche agreements void. According to the complaint, Genentech's directors have a fiduciary duty to non-Roche shareholders to...
Source Info
Malaysia Sun
http://story.malaysiasun.com/index.php/ct/9/cid/d805653303cbbba8/id/16565493/
Hello... Welcome to Employment Crossing News... I'm Evangeline Fabia. Pharmaceutical company, Roche, announced plans to move their New Jersey headquarters across the continent all the way to San Francisco, California. As a result, 374 workers at the current Nutley manufacturing facility are questioning the future of their jobs as the building will shut down. However, from tragedy to triumph... Roche said it will grow its research and development operations in the east coast. James Hughs ...
Excerpt
...have become the topic of intense speculation among investors. "Our aim is to reach a mutually agreed transaction," Roche said. Genentech has managed to preserve a considerable degree of autonomy since Roche acquired majority control in 1990. The innovative...
Source Info
San Francisco Chronicle
http://feeds.sfgate.com/~r/sfgate/rss/feeds/business/~3/346293580/article.cgi
Excerpt
...Roche also has many other powers of control under its many agreements with Genentech. By virtue of its control power, Roche controls Genentech and its board of directors, ensuring that the Genentech Board is conflicted and cannot act effectively on behalf...
Source Info
PR-Inside.com
http://www.pr-inside.com/on-july-22-2008-chimicles-r720779.htm
Excerpt
...provisions defining Roche's option to reacquire full ownership. Language in the affiliation agreement between Roche and Genentech lays out two routes by which Roche could have completed a purchase of Genentech. First, it could have asked for the approval...
Source Info
San Francisco Chronicle
http://feeds.sfgate.com/~r/sfgate/rss/feeds/business/~3/345320531/article.cgi
Roche aims to buy remaining shares of Genentech; Drugmakers are expanding into generics, emerging markets to lift sales; Analysis by Rhenu Bhuller of Frost & Sullivan
Roche Holding offered to buy Genentech Inc for $43.7B. Meanwhile, Suez Environnement says the reference price for the company?s initial listing of shares July 22nd will be between 14-20 Euros.
Roche Holding offered to buy Genentech Inc for $43.7B. Meanwhile, Suez Environnement says the reference price for the company?s initial listing of shares July 22nd will be between 14-20 Euros.
Excerpt
...the remaining shares of Genentech that it did not already own for $89 per share, for a total price of $43 billion. Roche is Genentech’s majority shareholder, owning more than 50% of the Company. The complaint alleges that the Proposal is unfair and inadequate...
Source Info
24x7 Wall St.
http://www.247wallst.com/2008/07/genentech-roche.html
Update Sources